Artificial Pancreas Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Summary
GlobalData's Medical Devices sector report, “Artificial Pancreas Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update provides comprehensive information about the Artificial Pancreas pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Artificial Pancreas helps people with diabetes, primarily type 1, automatically and continuously control their blood glucose level by providing the substitute endocrine functionality of a healthy pancreas.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Artificial Pancreas under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Artificial Pancreas and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Artificial Pancreas under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
1 About GlobalData
2 Table of Contents
2.1 List of Tables
2.2 List of Figures
3 Introduction
3.1 Artificial Pancreas Overview
4 Products under Development
4.1 Artificial Pancreas - Pipeline Products by Stage of Development
4.2 Artificial Pancreas - Pipeline Products by Territory
4.3 Artificial Pancreas - Pipeline Products by Regulatory Path
4.4 Artificial Pancreas - Pipeline Products by Estimated Approval Date
4.5 Artificial Pancreas - Ongoing Clinical Trials
5 Artificial Pancreas - Pipeline Products under Development by Companies
5.1 Artificial Pancreas Companies - Pipeline Products by Stage of Development
5.2 Artificial Pancreas - Companies Pipeline Products by Stage of Development
6 Artificial Pancreas Companies and Product Overview
Table 60: DBLG1 - Pediatric Version - Product Status
Table 61: DBLG1 - Pediatric Version - Product Description
Table 62: Diabeloop SA - Ongoing Clinical Trials Overview
Table 63: DBLG1 - Adults - An Open-label, Multicenter, Randomized, Crossover Study, to Assess 4 Weeks Outpatient, the Clinical Efficacy of the Diabeloop Closed-loop Glucose Control without the Declaration of Meals Compared with the Diabeloop Closed-loop Glucose Control with the Declaration of Meals, in Adolescent Patients with Type 1 Diabetes Poorly Controlled
Table 64: DBLG1 - Adults - Closed-Loop Insulin Delivery in Pregnant Women with Type 1 Diabetes
Table 65: DBLG1 - Adults - Interventional Before/After Study of the Effect of the DBLG1 System with TERUMO MEDISAFE with Insulin Pump on Glucose Control of Patients With Type 1 Diabetes in France. The BETTER Trial
Table 66: DBLG1 - Adults - Observational Study of the Use of DBLG1 System in Real Life
Table 86: Fusion System - Demonstration of an Artificial Intelligence Based Closed Loop Glucose Control System as a Therapeutic Modality in Type 1 and Type 2 Diabetic Patients
Table 87: Fusion System - Prospective Randomized Controlled Trial For Use of the FUSION Artificial Pancreas System as a Therapy for COVID-19
Table 88: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview
Table 89: Bio-inspired Artificial Pancreas - Product Status
Table 136: SynerG - A 48hr Study to Test Feasibility of the Pacific Diabetes Technologies Continuous Glucose Monitor Infusion Set (CGMIS) Sensing Interstitial Glucose Continuously in the Immediate Vicinity of SQ Insulin Delivery in Adults With T1 Diabetes
Table 137: SynerG - Assessment of an Integrated Continuous Glucose Monitor and Insulin Injection Port in Type 2 Diabetes